Table 2
Frequency of clinical parameters and raised immunohistochemical markers in NSCLC tumour specimens
| Parameters | Total | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Total | 79 | EGFR | cerbB2 | cerbB3 | bcl-2 | p53 | Ki-67 | p120 | MVD |
| The bold numbers indicate a significant correlation between the two parameters (Pearson χ2 test, p < 0.05). | |||||||||
| AC, adenocarcinoma; EGFR, epidermal growth factor; IHC, immunohistochemistry; LCC, large cell carcinoma; NSCLC, non-small cell lung cancer; MVD, microvessel density; SCC, small cell carcinoma. | |||||||||
| Clinical parameters | |||||||||
| AC | 37 | 11 | 16 | 17 | 16 | 13 | 13 | 21 | 11 |
| SCC | 37 | 19 | 12 | 27 | 7 | 15 | 24 | 23 | 17 |
| LCC | 3 | 1 | 1 | 2 | 2 | 1 | 0 | 1 | 1 |
| Carcinoid | 2 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
| Death | 26 | 9 | 10 | 18 | 7 | 10 | 11 | 14 | 10 |
| IHC | |||||||||
| EGFR | 32 | – | 10 | 22 | 9 | 9 | 18 | 19 | 10 |
| c-erbB-2 | 29 | 10 | – | 21 | 8 | 12 | 15 | 22 | 5 |
| c-erbB-3 | 46 | 22 | 21 | – | 12 | 18 | 28 | 31 | 18 |
| bcl-2 | 26 | 9 | 8 | 12 | – | 8 | 12 | 13 | 11 |
| p53 | 29 | 9 | 12 | 18 | 8 | – | 18 | 22 | 12 |
| Ki-67 | 36 | 18 | 15 | 28 | 12 | 18 | – | 25 | 13 |
| p120 | 46 | 19 | 22 | 31 | 13 | 22 | 25 | – | 19 |
| MVD | 29 | 10 | 5 | 18 | 11 | 12 | 13 | 19 | – |
| CD3 | 7 | 2 | 2 | 5 | 4 | 4 | 3 | 3 | 2 |
| CD19 | 39 | 14 | 16 | 26 | 17 | 17 | 21 | 21 | 5 |
